Federated Hermes Inc. Acquires 21,767 Shares of Codexis, Inc. (NASDAQ:CDXS)

Federated Hermes Inc. raised its holdings in Codexis, Inc. (NASDAQ:CDXS) by 1.7% during the 4th quarter, HoldingsChannel.com reports. The fund owned 1,278,126 shares of the biotechnology company’s stock after acquiring an additional 21,767 shares during the quarter. Federated Hermes Inc.’s holdings in Codexis were worth $6,097,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Tallon Kerry Patrick purchased a new position in Codexis in the fourth quarter worth $2,018,000. Vanguard Group Inc. lifted its stake in Codexis by 7.5% during the fourth quarter. Vanguard Group Inc. now owns 4,463,801 shares of the biotechnology company’s stock worth $21,292,000 after purchasing an additional 311,082 shares during the last quarter. Telemark Asset Management LLC boosted its holdings in shares of Codexis by 11.3% in the 4th quarter. Telemark Asset Management LLC now owns 3,000,000 shares of the biotechnology company’s stock worth $14,310,000 after purchasing an additional 303,589 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Codexis by 12.9% during the 4th quarter. Geode Capital Management LLC now owns 1,855,514 shares of the biotechnology company’s stock valued at $8,853,000 after purchasing an additional 211,475 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Codexis by 484.4% during the 4th quarter. JPMorgan Chase & Co. now owns 183,906 shares of the biotechnology company’s stock valued at $877,000 after buying an additional 152,438 shares in the last quarter. Institutional investors own 78.54% of the company’s stock.

Codexis Stock Performance

NASDAQ:CDXS opened at $2.35 on Friday. The company has a market capitalization of $194.67 million, a price-to-earnings ratio of -2.70 and a beta of 2.35. The business has a 50 day moving average of $3.14 and a 200 day moving average of $3.88. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.21 and a quick ratio of 3.15. Codexis, Inc. has a 1-year low of $1.90 and a 1-year high of $6.08.

Codexis (NASDAQ:CDXS) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.09). Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. The business had revenue of $21.46 million for the quarter, compared to analysts’ expectations of $27.41 million. On average, sell-side analysts predict that Codexis, Inc. will post -0.77 earnings per share for the current fiscal year.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.